The Business Research Company’s report on the Next-Generation Antibody Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the next-generation antibody therapeutics market further?
The increasing prevalence of chronic diseases is expected to propel the growth of the next-generation antibody therapeutics market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Next-generation antibody therapeutics have a therapeutic function for individuals with chronic illnesses that deliver more focused care, which would benefit patients’ outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing prevalence of chronic diseases is driving the growth of the next-generation antibody therapeutics market.
Access Your Free Sample of the Global Next-Generation Antibody Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp
What are the key factors influencing the forecasted market size of the next-generation antibody therapeutics industry?
The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.82 billion in 2024 to $7.63 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to monoclonal antibody success, rising prevalence of chronic diseases, approval of antibody-drug conjugates, growth of immunotherapy, gene therapy and antibodies
The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $11.52 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, real-world evidence in antibody development.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp
Who are the leading competitors in the next-generation antibody therapeutics market?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.
Which emerging trends are set to transform the next-generation antibody therapeutics market landscape?
Technological advancements are a key trend gaining popularity in the next-generation antibody therapeutics market. Major companies operating in the next-generation antibody therapeutics market are focused on developing technological advancements such as proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to enhance protein identification and characterization, leading to more targeted and effective treatments. As a result, these advancements aim to improve therapeutic profiles, reduce costs, and address complex diseases with greater precision. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a technology that organizes protein molecules into structured assemblies for enhanced analysis and quantification. It improves sensitivity and accuracy in protein detection, useful in research and diagnostics. For instance, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, launched a next-generation antibody profiling platform, that utilizes MIPSA technology for high-throughput, cost-effective analysis of immune responses, aiming to enhance disease understanding and personalize treatment strategies.
How do different geographies compare in terms of market share and growth potential in the next-generation antibody therapeutics market?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
Which major segments of the next-generation antibody therapeutics market are experiencing the fastest growth?
The next-generation antibody therapeutics market covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12678
How is the next-generation antibody therapeutics market defined, and what are its core characteristics?
Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic potential beyond traditional monoclonal antibodies. It treats several severe medical problems, including cancer, infectious infections, and immunological disorders.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
